Two-component vasopressor therapy for septic shock

The objective: to investigate the efficacy and safety of terlipressin when it is used as an additional vasopressor in septic shock.Subjects: A single-center, observational, retrospective-prospective study of the efficacy and safety of combined therapy of septic shock with norepinephrine and terlipre...

Full description

Saved in:
Bibliographic Details
Main Authors: A. A. Kochkin, V. V. Likhvantsev, К. К. Kadantseva
Format: Article
Language:Russian
Published: New Terra Publishing House 2021-03-01
Series:Вестник анестезиологии и реаниматологии
Subjects:
Online Access:https://www.vair-journal.com/jour/article/view/498
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849343978026041344
author A. A. Kochkin
V. V. Likhvantsev
К. К. Kadantseva
author_facet A. A. Kochkin
V. V. Likhvantsev
К. К. Kadantseva
author_sort A. A. Kochkin
collection DOAJ
description The objective: to investigate the efficacy and safety of terlipressin when it is used as an additional vasopressor in septic shock.Subjects: A single-center, observational, retrospective-prospective study of the efficacy and safety of combined therapy of septic shock with norepinephrine and terlipressin versus monotherapy with norepinephrine was conducted.Results. The use of terlipressin made it possible to reduce the average daily need for noradrenaline in patients with septic shock from 0.68 μg · kg-1 · min-1 in the control group to 0.55 μg · kg-1 · min-1 in the study group (p = 0.015) and reduce the duration of vasopressor support from 8 days [6.0-11.0] to 6 days [5.0-8.0] in the study group (p = 0.023). The use of terlipressin did not reduce the need for mechanical ventilation, but it did reduce the duration of ventilation.  The number of days free from mechanical ventilation in patients in the control group was 6.0 [1.0-18.0], in the study group - 16.0 [2.0-22.0], (p = 0.039).Conclusion. The use of terlipressin as a supplement to norepinephrine is an effective and relatively safe treatment for hypotension in refractory septic shock.
format Article
id doaj-art-1c16897e85b84ac3ad80a7575db20fbc
institution Kabale University
issn 2078-5658
2541-8653
language Russian
publishDate 2021-03-01
publisher New Terra Publishing House
record_format Article
series Вестник анестезиологии и реаниматологии
spelling doaj-art-1c16897e85b84ac3ad80a7575db20fbc2025-08-20T03:42:48ZrusNew Terra Publishing HouseВестник анестезиологии и реаниматологии2078-56582541-86532021-03-01181576410.21292/2078-5658-2021-18-1-57-64428Two-component vasopressor therapy for septic shockA. A. Kochkin0V. V. Likhvantsev1К. К. Kadantseva2M.F. Vladimirsky Moscow Regional Research Clinical InstituteM. F. Vladimirsky Moscow Regional Research Clinical Institute; V. A. Negovsky Scientific Research Institute of General ReanimatologyV. A. Negovsky Scientific Research Institute of General Reanimatology; A. S. Loginov Moscow Clinical Scientific CenterThe objective: to investigate the efficacy and safety of terlipressin when it is used as an additional vasopressor in septic shock.Subjects: A single-center, observational, retrospective-prospective study of the efficacy and safety of combined therapy of septic shock with norepinephrine and terlipressin versus monotherapy with norepinephrine was conducted.Results. The use of terlipressin made it possible to reduce the average daily need for noradrenaline in patients with septic shock from 0.68 μg · kg-1 · min-1 in the control group to 0.55 μg · kg-1 · min-1 in the study group (p = 0.015) and reduce the duration of vasopressor support from 8 days [6.0-11.0] to 6 days [5.0-8.0] in the study group (p = 0.023). The use of terlipressin did not reduce the need for mechanical ventilation, but it did reduce the duration of ventilation.  The number of days free from mechanical ventilation in patients in the control group was 6.0 [1.0-18.0], in the study group - 16.0 [2.0-22.0], (p = 0.039).Conclusion. The use of terlipressin as a supplement to norepinephrine is an effective and relatively safe treatment for hypotension in refractory septic shock.https://www.vair-journal.com/jour/article/view/498sepsisseptic shockvasopressor supportterlipressin
spellingShingle A. A. Kochkin
V. V. Likhvantsev
К. К. Kadantseva
Two-component vasopressor therapy for septic shock
Вестник анестезиологии и реаниматологии
sepsis
septic shock
vasopressor support
terlipressin
title Two-component vasopressor therapy for septic shock
title_full Two-component vasopressor therapy for septic shock
title_fullStr Two-component vasopressor therapy for septic shock
title_full_unstemmed Two-component vasopressor therapy for septic shock
title_short Two-component vasopressor therapy for septic shock
title_sort two component vasopressor therapy for septic shock
topic sepsis
septic shock
vasopressor support
terlipressin
url https://www.vair-journal.com/jour/article/view/498
work_keys_str_mv AT aakochkin twocomponentvasopressortherapyforsepticshock
AT vvlikhvantsev twocomponentvasopressortherapyforsepticshock
AT kkkadantseva twocomponentvasopressortherapyforsepticshock